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Anemia of uremia Is associated with reduced in vitro cytoklne secretion:
Immunopotentlating actIvIty of red blood cells. Many in vitro studies
demonstrate various stimulatory effects of red blood cells (RBC) on T
cell reactivity. Only a few suggest a role for RBC in vivo, such as
decreased B and T cell function in iron deficiency anemia. Immune
deficiency of uremia is only partially corrected by dialysis treatment.
We postulated therefore that this anemia may contribute in part to the
immune deficiency of uremia. The aim of our study was to evaluate this
postulate and to investigate the role RBC may have in the immune
system in vivo. The in vitro secretion of interleukin-2 (IL-2), tinter-
feron (y-IFN), tumor necrosis factor (TNF) and colony stimulating
factor (CSF) by human peripheral blood mononuclear cells isolated
from patients and controls was used as a measure of immune function,
The following protocols were carried out: IL-2 secretion was measured
in patients with end-stage renal disease (ESRD) and in controls. RBCs
were transfused to patients with ESRD and secretion of cytokines was
measured before, and 4 hours, 4, 7 and 14 days afterwards; patients
with ESRD received recombinant human erythropoietin (rHuEpo) and
secretion of cytokines was measured before treatment and two and four
months later. Finally, the effect of phlebotomy and transfusion of the
autologous blood on cytokine secretion in healthy subjects was mea-
sured. Secretion of IL-2 by patients with ESRD was substantially lower
than that of healthy subjects. In each group, IL-2 secretion correlated
positively with hemoglobin level, r = 0.73, Pc 0.01 and r = 0.71, Pc
0.01. Following transfusion of RBC, secretion of all cytokines rose at
the early stage of the study and stayed elevated throughout the study
period. Following treatment with rHuEpo secretion of the four cyto-
kines rose progressively and in parallel to the rise in hemoglobin level
as shown by a positive correlation between each of the cytokines and
the hemoglobin level. Phlebotomy caused a significant reduction in the
secretion of the four measured cytokines. Transfusion of autologous
blood led to a significant rise in cytokine secretion above prephlebot-
omy levels which persisted throughout the study. These results suggest
that the anemia of uremia may be associated with a decreased secretion
of cytokines in vitro. This could contribute to the impaired immune
response observed in patients with ESRD. Furthermore, RBC appear to
potentiate secretion of cytokines. The decreased secretion of cytokines
may be corrected in part by RBC transfusion or elevation of hemoglobin
levels with rHuEpo treatment.
In vitro studies have demonstrated various stimulatory ef-
fects of red blood cells (RBC) on T cell reactivity. RBC have
been shown to enhance the response to PHA [1] and natural
killer mediated cytotoxicity [2]. Human RBC have been shown
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to potentiate the response of peripheral blood mononuclear
cells (PBMC) to pokeweed mitogen [3], and to facilitate the
induction of primary and secondary specific antibody responses
in vitro by mononuclear cells [4]. Furthermore, B and T
lymphocyte colony formation was significantly enhanced by
sheep RBC added to the culture medium [5, 6]. In a recent
study, RBC were found to enhance secretion of various cyto-
kines by human PBMC and mouse spleen cells [7]. In contrast,
data on the in vivo effects of RBC are limited. Whole blood
transfusion (BT) has been shown to increase renal allogralt
survival [8, 9], probably due to immune suppression [10, 11]. A
suppressive effect of this kind was also obtained with the
transfusion of leukocytes [12] but not with leukocyte free RBC,
which caused a decrease in graft survival in a few patients [13].
This may suggest an immune stimulatory effect of RBC in vivo.
Indeed, a decrease in various T and B cell functions has been
described in children [14] and mice [15] with iron deficiency
anemia.
Uremia is an immune suppressed state [16]. Various factors
cause this immune suppression [17, 18]. Despite efficient dial-
ysis treatment, several suppressed immune functions are not
corrected. Since uremia is almost invariably associated with
anemia, we postulated that the immune deficiency of uremia
might be associated in part with the anemia.
The aim of this study was twofold. To evaluate a possible
contributory effect of anemia to immune deficiency of uremia,
and to investigate a potentiating effect of RBC on PBMC in vivo
as expressed by in vitro secretion of cytokines.
Patients with end-stage renal disease (ESRD) and anemia,
and healthy volunteers were studied. Cytokine secretion by
PBMC was used as a measure of immune competence and
function. Several protocols investigated the effect of changes in
hemoglobin on cytokine secretion. In the first protocol the
correlation between hemoglobin levels and interleukin-2 (IL-2)
secretion was investigated in normal subjects and in a cohort of
ESRD patients. In the second, the effect of an increase in
hemoglobin induced by a single leukocyte-poor washed red
blood cell (WRBC) transfusion on cytokine secretion by ESRD
patients was studied. Studies were performed 4 hours, 4, 7, and
14 days after WRBC transfusion. In the third protocol, the
effect of a gradual rise in hemoglobin induced by recombinant
human erythropoietin (rHuEpo) administration on cytokine
secretion was studied. The fourth protocol investigated the
effects of decreasing and increasing hemoglobin levels on
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cytokine secretion in healthy volunteers. Phlebotomy and au-
tologous WRBC transfusion were used to manipulate the he-
moglobin level. The cytokines studied included IL-2, y-inter-
feron (y-IFN), tumor necrosis factor (TNF) and colony
stimulating factor (CSF).
The results of the study suggest that the RBC have an
immunopotentiating effect demonstrated by their ability to
increase cytokine secretion. Anemia of uremia is associated
with a decreased ability to secrete cytokines which might be
partially restored with rHuEpo treatment.
Methods
Subjects
The patient cohort consisted of ESRD patients who were
undergoing regular dialysis treatment for at least six months.
None had received blood transfusions for at least three months
prior to the study. Normal volunteers served as controls.
Informed consent was obtained from all participants.
Protocol 1—Association between IL-2 and hemoglobin
IL-2 secretion by PBMC was measured in 15 patients with
ESRD whose age was 45 5 years. They received regular
hemodialysis treatment four hours thrice weekly with a Cu-
prophan membrane dialyzer and acetate containing dialysate.
The diseases which led to ESRD were: chronic glomerulone-
phritis (4 patients), interstitial nephropathy (2), refiux nephrop-
athy (2), diabetic nephropathy (2), atherosclerotic renal artery
occlusion (1), systemic lupus erythematosus (SLE) (1), and
unknown etiology (2). These patients were on dialysis for six
months to 12 years. They did not suffer from a recent infection
and were not treated with immunosuppressive drugs. They had
not received blood transfusions for at least three months prior
to the study and had not been treated with rHuEpo. Two of
them received a kidney transplant which was rejected 10 and six
years prior to the study. The patient with SLE has been on
hemodialysis for 12 years; her disease was already inactive
when dialysis was initiated. Twenty volunteers whose age was
42 1 years served as control. Hemoglobin, urea and creati-
nine were measured simultaneously.
Protocol 2—Effect of RBC transfusion on cytokine secretion
Six patients with ESRD received a transfusion of WRBCs.
The RBCs were washed three times and infused to the patients
through a nylon filter (Miramed, Mirandola, Italy) to obtain a 97
to 98% leukocyte free unit. The transfusion was given on a day
between dialyses. Blood samples were obtained pre-transfusion
and at 4 hours, 4, 7 and 14 days post-transfusion. Blood samples
on days 4, 7 and 14 were obtained prior to hemodialysis. PBMC
were isolated, and IL-2, y-IFN, TNF and CSF secretion were
determined. Post-transfusion results were compared to pre-
transfusion results which served as controls.
Protocol 3—Effect of rHuEpo on cytokine secretion
(a) Five women with ESRD on regular hemodialysis treatment
were studied. They received rHuEpo (Eprex, Cilag, Swit-
zerland) at a dose of 50 U/kg body weight X 3/week. After
a month, the dose was increased to about 75 U/kg x 3/week
and this dose was sustained throughout the study. Cytokine
secretion was determined before initiating rHuEpo treat-
ment, and after two and four months of treatment. The
determinations of IL-2 and y-IFN were performed with both
bio- and immunoassays. One patient underwent a cadaver
kidney transplantation just prior to the final cytokine secre-
tion determination.
(b) The in vitro effect of rHuEpo on IL-2 secretion was
examined. rHuEpo at a final concentration of 0.1, 0.5, 1, 10,
50 and 100 U/ml was added to the PBMC in culture. IL-2
secretion was measured as described.
Protocol 4—Effect of phlebotomy andautologous RBC
transfusion on cytokine secretion
Eleven volunteers, nine women and two men, whose age was
42 5 years were studied. One unit of blood (approximately
450 ml) was phlebotomized into a double blood pack and stored
at 4°C. Three weeks later, each subject was transfused with his
own RBCs following leukocyte removal as described in Proto-
col 2.
Cytokine secretion was measured before phlebotomy and at
one and three weeks postphlebotomy prior to autotransfusion.
One and two weeks post-transfusion samples were also
obtained. The interval between phlebotomy and autotransfu-
sion was chosen since preliminary studies have indicated res-
toration of the hemoglobin level three weeks postphlebotomy.
Reagents
Reagents used in this study were Concanavalin A (Con A;
Miles Yeda, Rehovot, Israel); phytohemagglutinin (PHA-M;
Difco Lab., St. Louis, Missouri, USA); lipopolysacharide (LPS
from S. Abortus Equi; Difco Lab., Detroit, Michigan, USA);
actinomycin D (Dactinomycin, Merck, New Jersey, USA); fetal
calf serum (FCS; Maagar, Beit Haemek, Israel). Enriched
RPMI-1640 (GIBCO) was supplemented with 10% FCS, 2 mM
L-glutamine, 10 m nonessential amino acids, 3 m sodium
pyruvate, 5 X iO- M 2-ME, 100 IU/ml penicillin, and 100 g/ml
streptomycin.
Cell preparation
PBMC were isolated following Ficol-Hypaque gradient cen-
trifugation. The isolated PBMC were washed and suspended in
enriched RPMI-1640 at a concentration of 106/ml.
Quantitation of IL-2
Bioassay. The ability of the supernatant fraction to support
the growth of the IL-2 dependent CTLL clone was used to
assay IL-2 production. CTLL cells (10 per well) were seeded in
triplicates in culture medium, with or without dilutions of the
supernatant fraction. After 48 hours, 3H-TdR uptake was de-
termined in a liquid scintillation counter. One unit of IL-2
activity was defined as the reciprocal log2 dilution required to
give 50% of the maximal proliferation of io IL-2 dependent
murine CTLL cells after 48 hours of culture.
Immunoassay. Quantitative measurements of IL-2 in the
supernatants were carried out with an enzyme-linked Elisa
immunoassay kit (T- Cell Diagnostic Inc., Cambridge, Massa-
chusetts, USA).
Assay for CSF activity
CSF was quantitated by determining the number of colonies
that developed from blood mononuclear (BM) cells cloned in
the presence of the CSF-containing fraction to be tested. The
soft agar technique described by Pluznik and Sachs [19] was
used to clone BM cells. Briefly, supernatants containing CSF
were incorporated in 2 ml of hard medium in a 35 mm Petri dish.
iO BM cells in 1 ml of soft agar medium (0.3%) were cloned
above the hard agar layer. After seven days of incubation at
37°C in a humidified atmosphere of 8.5% CO2 in air, the number
of colonies that had grown in the soft agar layer was scored.
Assay for tumor necrosis factor
Murine connective tissue cells (LM) were seeded into all
wells of 96-well flat bottom microtiter plates at a density of 4 x
iO cells/well in 100 1.d of culture medium (M 199/0.5% peptone)
and incubated for 24 hours at 37°C. Spent medium was removed
and replaced with 100 tl M 199/0.5% peptone supplemented
with 2 g/m! actinomycin D. One hundred microliters of two-
fold dilutions of the samples tested for TNF were placed into
the wells. Control wells consisted of LM cells in culture
medium without TNF. Plates were incubated for 24 hours at
37°C. Titers were expressed as the reciprocal of the dilution
resulting in 50% cytotoxicity of control wells. No differentiation
is made in this assay between TNF-a and TNF-f3.
Assay for y-interferon quantitation
Bioassay. y-IFN activity was measured using a cytopathic
effect reduction assay. In short, serial twofold dilutions of test
samples were made in 100 p Dulbecco's minimal essential
medium (DMEM) in flat-bottomed microplates. One hundred
microliters of human epithelial Hep2 cells were added at 5 X i0
cells/mi in DMEM supplemented with 10% FCS to each well.
Alter overnight incubation at 37°C in a humidified CO2 incuba-
tor, confluent cell monolayers were challenged with 50 ,al
Vesicular Stomatitis virus (VSV) at a multiplicity of infection of
about one. Protection against the cytopathic effect (CPE) of the
virus was recorded 24 hours later, and y-IFN titers were
expressed as the reciprocal of the last dilution of the test sample
at which a 50% protection against CPE was still visible. Data
were expressed in laboratory units per milliliter.
Immunoassay. Quantitative measurements of 'y.IFN in the
supernatants were carried out with an enzyme-linked Elisa
immunoassay-kit (T- Cell Diagnostic Inc., Cambridge, Massa-
chusetts, USA).
Production of cytokines
Human PBMC 106/ml cells were suspended in enriched
RPMI-1640 medium with 10% FCS and 200 j.tg/ml PHA-M. The
cultures were incubated for 48 or 96 hours. Supernatants were
collected and assayed for either IL-2, or CSF (after 48 hr of
incubation) or for TNF and y-IFN (after 96 hr of incubation).
Rat spleen cells, treated by hypotonic shock to lyze erythro-
cytes, were cultured at 5 x 106/ml for 48 hours (for IL-2 and
CSF) or 1 x 106/ml for 24 hours (for IL-3) in enriched RPM!-
1640 medium with 10% FCS and 2.5 sg/ml Con A. Supernatants
were collected and tested for the specific cytokines.
Statistical analysis
Data are presented as mean SE. Comparisons between
groups were made with the Student's t-test for paired or
unpaired data as needed. Pearson's correlation coefficient was
calculated for analysis of correlations between IL-2 secretion
and hemoglobin level in protocol 1, and for correlations be-
tween results of bioassays and immunoassays of IL-2 and
y-IFN in protocol 3. Correlations between secretion of various
cytokines and hemoglobin levels at the different time points in
protocols 3 and 4 were analyzed using multiple analysis of
variants (MANOVA) with repeated measures.
Results
Association between IL-2 and hemoglobin
The secretion of IL-2 by PBMC from patients with ESRD
was 7.7 1.6 U/mi significantly less than IL-2 secretion by the
control group (31.2 2.6; P < 0.001). Similarly, hemoglobin
levels of the patients with ESRD was much lower than that of
the controls (7.8 0.5 vs. 13.0 1.3 g/dl; P <0.005). Figure 1A
illustrates the correlation between IL-2 secretion and hemoglo-
bin levels of the patients with ESRD. A direct correlation was
found (r = 0.73, P < 0.01). The correlation between IL-2
secretion and hemoglobin levels of the controls is depicted in
Figure lB. A direct correlation was also found in this group
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Fig. 1. Correlation between JL-2 Secretion and blood hemoglobin
levels in patients with ESRD (r = 0.73, P < 0,01, N = 15) (A) and in
healthy subjects (r 0.71, P <0.01, N = 20) (8).
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Fig. 2. Effect of RBC transfusion on IL-2
secretion (A), y-IFN secretion (B), TNF
secretion (C), and CSF secretion (D), before
blood transfusion (BT) and 4 hours, 4, 7 and
14 days afterBT, (N = 6).
(r = 0.71, P < 0.01). No correlation was found between IL-2
and urea or creatinine.
Effect of RBC transfusion on cytokine secretion in patients
with ESRD
The acute effect of WRBC on cytokine secretion by PBMC is
illustrated in Figure 2. As shown in Figure 2A, a single
transfusion of RBC to patients with ESRD caused an immediate
rise in IL-2 from 6.5 5.1 to 11.8 7.2 U/ml (P < 0.05). Four
days later, the IL-2 level reached 14.4 7.7 U/mi (P < 0.025).
One week after the transfusion, IL-2 levels were 13.6 7.6
U/mi (P < 0.025). Two weeks after the transfusion, the IL-2
level was 12.2 8.4 U/mi, which was not different from
baseline. Figure 2B illustrates changes in y-IFN. The basal level
was 105 34 U/ml. After four hours it was 225 87 U/mi. Four
days after the transfusion, y-IFN rose significantly to 265 97
U/mi (P < 0.05); at one week it was slightly higher at 336 88
U/mi (P <0.01), and at two weeks it was 300 80 U/ml (P <
0.01). Figure 2C illustrates the changes in TNF post-transfu-
sion. The TNF level was 4 1.7 U/mi pre-transfusion and 12.8
5.3 U/ml four hours post-transfusion. After four days it was
still significantly elevated (8 2.2; P < 0.05); after one week it
was 16 5.7 (P < 0.05), and after two weeks 11.2 2.0 (P <
0.001). The changes in CSF are shown in Figure 2D. The
pattern of change was similar to that seen with the other
cytokines. The basal level of 39.2 3.4 coionies/105 bone
marrow cell (Co/BMC) rose to 51.2 5.1 Co/BMC four hours
after transfusion (P < 0.01). This level was sustained. It was
53.5 4.9 Co/BMC four days post-transfusion (P < 0.005), 52.4
4 Co/BMC one week post-transfusion (P < 0.005), and 64.2
8 two weeks post- transfusion (P < 0.02).
Effect of rHuEpo on cytokine secretion in patients with ESRD
The effect of a gradual change in hemoglobin on cytokine
secretion was evaluated in five women with ESRD who were
treated with rHuEpo intravenously. Their hemoglobin level
before the rHuEpo treatment was 6.1 0.4 g/dl. Two months
later it was 9.1 0.4 g/dl (P < 0.005), and after four months of
treatment it was 11.5 0.6 g/dl (P < 0.001). Changes in IL-2
secretion associated with rHuEpo treatment measured by the
bioassay are shown in Figure 3. The IL-2 level was 4.0 2.4
U/mi before rHuEpo treatment. After two months of treatment
it was 8.8 4.4 U/mi and after four months it rose to 21.5 5.7
U/mI (P < 0.01). Immunoassay measurements of IL-2 secretion
in this protocol were also performed. Before rHuEpo treatment
IL-2 level was 163 97 pg/ml. After two months of treatment it
was 325 145 pg/mI and after four months it rose significantly
to 658 73 pg/mi (P < 0.02). The bioassay determinations
showed a highly significant correlation with immunoassay de-
terminations (r = 0.937, P < 0.0001). To evaluate the correla-
tion between IL-2 secretion and the hemoglobin level at the
three time points MANOVA with repeated measures was used;
indeed, a positive correlation was found (P <0.015).
The response of y-IFN to rHuEpo treatment as determined
by the bioassay is shown in Figure 4. y-IFN concentration rose
from a level of 216 70 to 1152 192 U/mI after two months
(P < 0.005). This level was maintained at four months 1152
215 U/mI (P < 0.005). Measurement of )4FN by immunoassay
revealed a similar pattern to that found in the bioassay. Before
rHuEpo treatment 'y-IFN concentration was 323 85 pg/0. 1 ml,
after two months of treatment it rose to 1827 334 pgIO. 1 ml (P
< 0.005), and four months after the beginning of rHuEpo
treatment the y-IFN level was 1980 427 pg/0. 1 ml (P < 0.005).
The bioassay showed a positive correlation with the immuno-
assay (r = 0.997, P < 0.0001). A possible correlation between
y-INF secretion and the hemoglobin level at the different time
Gafter et a!: Immunopotentiation by red blood cells 227
U-z
I—
P<0.0130
20
C',
d 10
0
Pre
Time after treatment, months
Fig. 3. Effect of rHuEpo treatment in patients with ESRD on IL-2
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Fig. 5. Effect of rHuEpo treatment in patients with ESRD on TNF
secretion (N = 5).
points was tested using MANOVA with repeated measures. A
positive correlation was found (P < 0.018).
The effect of rHuEpo treatment on TNF secretion is shown in
Figure 5. TNF concentration rose from 9.6 2.7 U/mi before
treatment to 24.0 5.1 U/mI two months after initiation of
treatment (P < 0.01). After four months of treatment the level
was 44.0 12.0 U/mI (P < 0.025). Again a positive correlation
was found between TNF and hemoglobin levels (P < 0.013).
The response of CSF followed a similar pattern. Following two
months of treatment its concentration rose from 47.4 6.2
Co/BMC to 59.2 6.5 Co/BMC (P < 0.01). After four months
of treatment its concentration reached 70.3 4.5 Co/BMC (P <
0.01) (Fig. 6). A positive correlation between CSF secretion and
hemoglobin level was also found (P < 0.002).
During treatment with rHuEpo, serum ferritin level de-
creased in all patients. Before initiation of treatment with
rHuEpo, serum ferritin was 542.6 179.2 g/liter, after four
months of treatment it decreased to 412.8 158.7 pg/liter (P <
0.05).
In vitro effect of rHuEpo on IL-2 secretion by PBMC from
healthy subjects, Basal IL-2 secretion by PBMC was 24.5 3.1
U/ml, with the addition of 0.1 ilml rHuEpo, IL-2 secretion was
23.8 2.5 U/ml, with 1 U/mi rHuEpo it was 24.5 U/mi, and with
5 U/ml rHuEpo it was 26.8 3.4 UIml. mall cases the secretion
of IL-2 did not differ significantly from the basal level, nor did
the addition of 10, 50 and 100 U/mI of rHuEpo affect IL-2
secretion (26 4.3, 23.8 3.2 and 25,5 3.3 U/mI, respec-
tively).
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Fig. 7. Effect of phlebotomy and autologous BT on IL-2 secretion in
healthy subjects (N = 11).
Effect of phlebotomy and autologous RBC transfusion on
cytokine secretion in healthy subjects
The hemoglobin level prior to phlebotomy was 13.2 0.4
g/dl, one week post-phlebotomy it decreased significantly to
11.9 0.4 g/dl (P < 0.001), and three weeks postphlebotomy it
was 12.4 0.4 g/dl slightly less than the basal level (P < 0.001).
One week following the autologous WRBC transfusion, hemo-
globin levels rose to 13.5 0.5 g/dl and two weeks after
transfusion the hemoglobin level was 13.3 0.4 g/dl. Both
values were not different from the prephlebotomy hemoglobin
level. Figure 7A illustrates the response of IL-2 secretion. The
prephiebotomy level of 32.2 1.6 U/mi was decreased at one
week postphlebotomy to 25.2 1.5 U/ml (P < 0.001), and at
three weeks postphlebotomy the IL-2 secretion was 31.4 1.6
U/mi similar to the prephlebotomy level. One week after
autologous WRBC transfusion IL-2 secretion rose to 38.3
1.9, which was significantly higher than before phlebotomy (P
<0.001), and two weeks post-autologous WRBC transfusion it
was still elevated to 39.4 1.5 U/ml (P < 0.001 vs. prephie-
botomy). IL-2 secretion correlated directly with the hemoglobin
level at the different time points (P <0.0001).
The response of y-IFN is depicted in Figure 8. Prephlebot-
omy y-IFN secretion was 210.0 60.2 U/mi; one week post-
phlebotomy it decreased substantially to 73.1 23.2 U/ml (P <
0.0 1). The prephiebotomy secretion rate was obtained three
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weeks postphiebotomy (210.0 60.2 U/mi). Autologous trans-
fusion raised the y-IFN secretion rate to 639.5 140.3 U/mi (P
< 0.001 vs. prephlebotomy), and this elevated secretion rate
was sustained at two weeks post-transfusion 614.1 128.3 (P <
0.001 vs. prephiebotomy). A direct correlation was found
between y-IFN secretion and hemoglobin levels (P < 0.0001).
Figure 9 illustrates the TNF response. Prephiebotomy TNF
secretion was 139.6 28.4 U/mI. One week postphlebotomy it
decreased to 58.2 11.3 U/mi (P < 0.002) and by three weeks
postphlebotomy the secretion rate was restored (139.6 28.4
U/mi). RBC transfusion raised secretion of TNF to 343.3 52
U/mi (P < 0.001). This high secretion rate was maintained at
two weeks post-transfusion 331.6 46.3 U/mi (P < 0.001). A
direct correlation was found between TNF secretion and the
hemoglobin level (P < 0.0001).
Figure 10 shows the response of CSF. Prephiebotomy secre-
tion was 70.3 4.1 Co/BMC. One week postphlebotomy it
decreased to 49.9 2.7 Co/BMC (P < 0.001) and three weeks
postphelbotomy the secretion rate normalized at 70.3 5.3
Co/BMC. Following autologous WRBC transfusion, secretion
increased to 108.8 8.2 Co/BMC (P < 0.001). It further
increased to 119.1 8.8 Co/BMC (P < 0.001 vs. prephlebotomy
P < 0.005 vs. 1 week post-transfusion). CSF secretion corre-
lated directly with hemoglobin levels (P < 0.0001).
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This study suggests that the secretion of IL-2, 'y.IFN, TNF
and CSF by PBMC of anemic uremic patients is reduced.
Furthermore, the RBC seem to be an additional modulator of
the immune system, probably through the stimulation of cyto-
kine secretion. Several findings point to these conclusions: IL-2
secretion by PBMC of patients with ESRD and anemia was
lower than IL-2 secretion by control subjects. Moreover, the
IL-2 secretion correlated positively with the hemoglobin level
in both patients with ESRD and in the healthy controls. But in
patients with ESRD there was no correlation between IL-2
secretion and serum levels of urea or creatinine. Transfusion of
RBC to patients with ESRD led to a significant rise in the
secretion of IL-2, y-IFN, TNF and CSF. In addition, the
gradual rise in hemoglobin level obtained by rHuEpo enhanced
the secretion of these four cytokines to levels approaching
those of healthy subjects. Here again, secretion of IL-2, y.IFN,
TNF and CSF correlated directly with the hemoglobin level of
the patients with ESRD.
Phlebotomy in healthy subjects was associated with reduc-
tion in IL-2, y-IFN, TNF and CSF secretion which was
restored by three weeks in parallel with the spontaneous rise in
the hemoglobin level. Transfusion of autologous blood led to an
additional rise in the secretion of these cytokines. The changes
in cytokine secretion again correlated positively with those of
the hemoglobin level.
Two separate, although linked effects, on cytokine secretion
by PBMC in vitro emerged from these studies. One effect is
associated with the level of anemia and is expressed by direct
correlation between the secretion of cytokines in vitro and the
blood hemoglobin level. The other effect is related to the
immunomodulatory impact of acute RBC transfusion which is
observed early after transfusion and which lasts unrelated to the
hemoglobin level.
In vitro studies have demonstrated stimulation of T and B
cells by RBC [1-.7]. The present study demonstrates an in vivo
stimulation of PBMC by RBC which is manifested by enhanced
secretion of cytokines. This effect was obtained with both
homologous and autologous RBC, suggesting that it is indepen-
dent of the major histocompatibility complex. Similar results
were found in in vitro studies which showed enhancement of
PHA stimulation [1] and natural killer mediated cytotoxicity [2]
by autologous, homologous or heterologous RBC.
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Fig. 8. Effect of phlebotomy and autologous BT on '-IFN secretion in
healthy subjects (N = 11).
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Fig. 9. Effect of phlebotomy and autologous BT on TNF secretion in
healthy subjects (N 11).
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Activation of mononuclear cells by RBC could occur indi-
rectly as suggested by Tarnvik [1]. He postulated that the
increased response of mononuclear cells to PHA is achieved by
binding the mitogen to the RBC and presenting it to the
responding cell in a favorable manner.
Another possibility is a direct activation of lymphocytes by
RBC. The sheep RBC receptor (CD2) on human T lymphocytes
is a surface glycoprotein present on all mature T cells [20]. Its
natural ligand is a broadly distributed cell adhesion molecule
designated as lymphocyte function associated antigen 3
(LFA-3) [21]. Recently, this antigen has been shown to be
expressed on RBC [22, 23]. The interaction between CD2 and
its ligand LFA-3 has been shown to deliver activating signals to
human T lymphocytes [24]. The effect of RBC on lymphocytes
has been shown to be abrogated by preincubation of lympho-
cytes with anti-CD2 antibodies or by pretreatment of RBC with
anti-LFA-3 monoclonal antibodies [25, 261. A recent study from
our laboratory [7] has shown enhancement of the secretion of
various cytokines by human PBMC and mouse spleen cells in
the presence of autologous RBC. This enhanced secretion of
cytokines was abrogated when human PBMC and mouse spleen
cells were pretreated with human or mouse anti-CD2 antibod-
ies, respectively. This suggests that RBC may enhance cytokine
secretion via interaction between LFA-3 molecules on the RBC
and the lymphocyte CD2 molecules.
Other factors which may influence cytokine secretion inde-
pendently of RBC could include iron and rHuEpo. Iron defi-
ciency may impair lymphocyte proliferation [27], and indeed,
iron deficiency anemia has been associated with immune defi-
ciency [14, 15]. In the present study treatment with rHuEpo led
to a rise in hemoglobin levels and cytokine secretion with a
simultaneous decrease in the blood level of ferritin. It is
therefore unlikely that iron affected cytokine secretion. The
results in this study suggest that the effect of rHuEpo on
cytokine secretion is indirect through the RBC. This is based on
the direct correlation between hemoglobin levels and cytokine
secretion following rHuEpo treatment. Furthermore, a direct
correlation between the hemoglobin level and cytokine secre-
tion was found when the hemoglobin level was changed with
either transfusion or phlebotomy. These protocols have proba-
bly driven endogenous erythropoietin blood concentration in
the opposite direction of the hemoglobin level and cytokine
secretion. A direct effect of rHuEpo on IL-2 secretion by
PBMC was examined in the in vitro protocol. There was no
effect of rHuEpo in concentrations which ranged from physio-
logical up to 100,000 mU/mi. Similar results were reported from
other laboratories [28]. It is noteworthy that rHuEpo treatment
with 200 U/kg body weight daily given to candidates for major
cardiac surgery led to more than a three-fold increase in IL-2
secretion [29]. Contrary to its effect on T cells and monocytes,
rHuEpo seems to activate B cells directly. Treatment with
rHuEpo in patients with ESRD led to enhanced secretion of
immunoglobulins by PBMC which was independent of RBC
[28]. Moreover, the addition of rHuEpo Ui Vitro enhanced
secretion of IgG and IgA by PBMC [28] and the secretion of IgE
by PBMC isolated from atopic subjects [30]. It also enhanced
1gM secretion by a lymphoblastoid cell line [31]. The concen-
tration of rHuEpo in the in vitro studies was pharmacological.
In this study we employed protocols whereby RBC mass was
modulated in vivo, However, the effect of changes in the
hemoglobin level by rHuEpo treatment, phlebotomy or that of
RBC transfusion on PBMC was tested in vitro, that is, secretion
of cytokines in culture. Due to the limitations of the method
used, conclusions regarding clinical relevance need further
substantiation by clinical studies. It is noteworthy that treat-
ment with rHuEpo which raised the hemoglobin level in pa-
tients with ESRD led to a decrease or no change in other
immune functions. Thus, the response to PHA stimulation and
mixed lymphocyte reaction (MLR) were decreased [32] or
unchanged [33]. However, in cardiac surgery patients treatment
with rHuEpo increased the response to PHA stimulation [29].
Based on the reasults of this study augmentation of the re-
sponse to PHA stimulation and MLR would have been ex-
pected. However, data regarding PHA stimulation and MLR
are inconsistent. In addition, various immune responses may
react differently to similar stimuli. In clinical practice the
treatment with rHuEpo led to a reduction in the percent of
panel reactive antibodies (PRA%) in sensitized patients await-
ing kidney transplantation [32, 33]. This reduction in PRA% is
most probably the result of the decrease in the number of blood
transfusions [34].
A preliminary report suggested that pre-transplantation
rHuEpo treatment and a high pre-transpiantation hematocrit
were associated with a prolonged post-transplantation dialysis
and prolonged post-transplantation anuria [35].
In summary, taking into consideration the limitations of the
methodology used, the RBC seem to have a potentiating effect
on cytokine secretion. Anemia of patients with ESRD may be
associated with decreased cytokine secretion and thereby may
contribute to their immune deficiency. Treatment with rHuEpo
or RBC transfusion might restore in part the patients' ability to
secrete cytokines.
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